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The hallmarks of cachexia include the loss of leans mass due to disruption in 
muscle maintenance. Leucine has been shown to improve protein synthesis and 
mitochondrial biogenesis, key signaling pathways influenced by cachexia. This study 
aimed to elucidate the effects of leucine supplementation on mitochondrial biogenesis, 
within the Lewis Lung Carcinoma (LLC) implantation model of cancer cachexia. Twenty 
mice were divided into four equal groups (n = 5): Chow, leucine (Leu), LLC, LLC+Leu. 
At the age of 9-10 weeks, mice received a subcutaneous injection of 1x106 LLC cells or 
phosphate buffered saline (PBS). Leu groups were then switched to diet supplemented 
with 5% leucine (w/w) for 4 weeks. Within the gastrocnemius, protein synthesis and 
mitochondrial content were decreased in LLC. Peroxisome proliferator-activated receptor 
Gamma Co-activator 1-α (PGC-1α) within LLC+Leu was increased relative to LLC. 
Leucine was unable to preserve protein synthesis, mitochondrial content, and reduce 










Table of Contents 
Chapter          Page 
 
1 Introduction 1 
Cancer Cachexia 1 
Mitochondrial Function 5 
Leucine Supplementation 7 
 
2 Materials and methods 12 
Cell Culture 12 
Animals 13 
Run to Fatigue 14 
Fasting blood glucose 14 
Western Blot 15 
Statistical Analysis 16 
 
3 Results 16 
 
4 Discussion 19 
Limitations and Future Direction 29 
 
5 Tables 31 
 
6 Figures 34 
 
7 References 39 
 
8 Appendix 44 













List of Figures 
Figure           Page 
1.  Experimental Design         34 
2. Body mass and composition        35 
3. Endurance performance and fasting glucose     36 
4. Measures of mitochondrial biogenesis in the gastrocnemius    37 















Key to Symbols and Abbreviations 
ADP - Adenosine diphosphate 
Akt - Protein Kinase B 
AMP - Adenosine monophosphate 
AMPK - AMP-activated protein kinase 
ANOVA - Analysis of variance 
APR - Acute Phase Response 
ATP - Adenosine triphosphate 
BCAA – Branched Chain Amino Acid 
BCAT - Branched chain aminotransferase 
BSA – Bovine Serum Albumin 
Chow – Control diet 
CRP - C-reactive protein 
FOXO1 - Forkhead box protein O1 
Glut4 - Glucose transporter type 4 
HMB - β-hydroxy-β-methylbutyrate 
HRP - Horseradish Peroxidase 
IGF-1 - Insulin-like growth factor 1 
IL-6 - Interleukin 6 
IOD – Integrated optical density 
JNK - Jun N-terminal kinase 
Leu - Leucine supplemented 
LLC - Lewis Lung Carcinoma 
vii 
 
MAPK - Mitogen-Activated Protein Kinase 
MCK - Muscle Creatine Kinase 
mRNA - Messenger RNA 
mTOR – Mammalian Target of Rapamycin 
mtROS – Mitochondrial Reactive Oxygen Species 
NAD - Nicotinamide Adenine Dinucleotide 
NFκB - Nuclear Factor κ B 
NRF - Nuclear Respiratory Factor 
PBS – Phosphate Buffered Saline 
PGC-1α - Peroxisome proliferator-activated receptor Gamma Co-activator 1-α 
PIF - Proteolysis-Inducing Factor 
PPAR - Peroxisome Proliferator-Activated Receptors 
RNS - Reactive Nitrogen Species 
ROS - Reactive oxygen species 
RTF – Run to fatigue 
SEM - Standard Error of Mean 
SIRT1 – Sirtuin 1 
STAT3 - Signal transducer and activator of transcription 3 
TBST - Tris Buffered Saline with Tween® 20 
TFAM - mitochondrial transcription factor A 
TNFR1 - Tumor necrosis factor receptor 1 
TNFα - Tumor necrosis factor α 
TRAPS - TNFR1-associated periodic syndrome 
viii 
 
UCP - Uncoupling proteins 














Cachexia refers to the loss of body mass in the presence of an underlying chronic 
illness. In cancer patients in particular, cachexia affects a large portion of the population 
and is thought to be responsible for more than 30% of all cancer-related deaths (von 
Haehling & Anker, 2010). In contrast to typical anorexic weight loss, there is increased 
loss of muscle mass relative to fat mass, potentially modulated by metabolic disruption 
induced by the chronic inflammation associated with cancer. In various models of 
disease, loss of lean mass is an indicator of increased mortality (Nanri et al., 2010; 
Pocock et al., 2008). The loss of lean mass induced by cancer is commonly attributed to 
the decreased skeletal muscle protein synthesis and stimulation of proteolytic pathways.  
In response, nutritional interventions have been utilized to increase food intake, preserve 
body mass, and improve quality of life, with varying degrees of success. However, due to 
different methods, results from these studies do not demonstrate consistent preservation 
of body mass or lowering mortality (Baldwin, Spiro, Ahern, & Emery, 2012; Balstad, 
Solheim, Strasser, Kaasa, & Bye, 2014). These findings suggest the need for additional 
strategies for management of weight loss induced by cancer cachexia.  
Cancer Cachexia 
Although many definitions exist, cachexia generally refers to the loss of body 
mass, both muscle and fat mass, in the presence of an underlying chronic disease. This 
loss of body mass is generally accompanied by inflammation and alterations in metabolic 
pathways. Cachexia affects a significant portion of cancer patients and it is associated 
with increased morbidity and mortality in cancer patients (von Haehling & Anker, 2010).  
In various states of disease, significant loss of lean body mass is correlated with increased 
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mortality (Nanri et al., 2010; Pocock et al., 2008).  However, loss of body mass is not 
enough to identify cancer cachexia. Both systemic inflammation and reduced food intake 
can be factored in conjunction with loss of body mass to predict adverse functions of 
cachexia and poor prognosis (Fearon, Voss, Hustead, & Group, 2006).  
Reduction in food intake and hypermetabolism. Many cancer patients 
experience anorexia, likely induced by the disease and its accompanying treatments 
including chemotherapy, surgery, and radiotherapy. In a study of sixty six  cancer 
patients receiving end of life care, 61% had anorexia even though they were not receiving 
chemotherapy (Tranmer et al., 2003).  Additionally, there is increasing evidence that 
weight loss due to pathologically induced anorexia, from cancer, HIV, or sepsis, is 
inherently different from anorexia nervosa. In the case of anorexia nervosa, fat mass is 
often lost first in a higher proportion than lean body mass due to prolonged starvation 
with ketone bodies being produced for energy supplementation to the brain. In the 
pathologically induced anorexia, there is a larger portion of lean body mass loss relative 
to fat mass (Tisdale, 2009). Fortunately, loss of body mass due to cachexia responds well 
to oral nutritional support, as a meta-analysis reviewing 13 studies totaling 1,414 patients, 
has shown that interventions were associated with an increased energy intake of 430 
kcals per day and a weight gain of 1.9 kg over various durations (Baldwin et al., 2012). 
While nutritional intervention improved various quality of life factors, these studies were 
very heterogeneous and did not significantly affect mortality (Baldwin et al., 2012). 
When gastrointestinal function is impaired, oral nutrition can be supplemented with 
parenteral nutrition, providing caloric support to stabilize nutritional status (Pelzer et al., 
2010). The fact that simply increasing caloric intake does not consistently preserve 
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muscle mass or improve mortality suggests that there is more to cachexia than 
overcoming anorexia.  
In addition to anorexia, resting energy expenditure may be increased in various 
forms of cancer. Several factors may increase resting energy expenditure including 
increased acute phase response (APR), thermogenesis from skeletal muscle, or presence 
of brown adipose tissue (Tisdale, 2009). An increase in APR occurs when the liver 
changes protein synthesis from production of albumin to acute phase proteins such as C-
Reactive protein (CRP). In addition to increasing resting energy expenditure, induction of 
APR in cachectic patients has been linked to inflammation (Scott, McMillan, Crilly, 
McArdle, & Milroy, 1996; Staal-van den Brekel, Dentener, Schols, Buurman, & 
Wouters, 1995), muscle wasting (Bonetto et al., 2011), reduced quality of life and 
shortened survival (Falconer et al., 1995; Vaughan, Martin, & Lewandowski, 2013). The 
increased thermogenesis from skeletal muscle and “browning” of adipose tissue is caused 
by increased expression of uncoupling proteins (UCPs) that mediate the proton gradient 
in the mitochondria. In the muscle, increased levels of UCP3 mRNA was associated with 
weight loss in adenocarcinoma patients (Collins, Bing, McCulloch, & Williams, 2002). In 
the MAC16 adenocarcinoma mouse model of cancer cachexia, UCP1 was elevated in 
adipose tissue while UCP2 and UCP3 were elevated in the muscle of tumor bearing 
groups (Bing et al., 2000). Both factors highlight cancer induced metabolic inefficiencies 
additively contribute to cachexia.   
In some cancer patients, the total energy expenditure may be lower relative to that 
of a healthy individual, despite increased resting energy expenditure. Understandably, 
this is commonly attributed to the lack of physical activity in the cachectic population 
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(Moses, Slater, Preston, Barber, & Fearon, 2004). Inactivity is not only associated with 
increased systemic inflammation, but lower quality of life as well (Fischer, Berntsen, 
Perstrup, Eskildsen, & Pedersen, 2007; Tisdale, 2009). While physical activity provides 
many metabolic benefits, counteracting inflammation and improving mitochondrial 
function, exercise may not be possible for those in advanced stages of cancer. In addition 
to physical inactivity, there is also evidence that disturbances in mitochondrial function 
and elevations in APR are associated with chronic inflammation induced by cachexia.  
A key metabolic factor modulated by cancer cachexia is mitochondrial function. 
Due to increased inflammatory signaling and generation of reactive oxygen species 
(ROS) during cancer cachexia, mitochondrial biogenesis and function may be impaired. 
Various models of cancer cachexia exhibit decreased Peroxisome proliferator-activated 
receptor Gamma Co-activator 1-α (PGC-1α) expression and mitochondrial dysfunction in 
the presence of increased IL-6 and weight loss (Eley, Russell, & Tisdale, 2007; White et 
al., 2011). This impairment may affect the efficiency of metabolism and energy balance, 
consequently influencing weight loss. While these effects can be attenuated by exercise 
(Puppa et al., 2012), other strategies in conjunction with exercise could be developed to 
further preserve muscle mass and mitochondrial function.  
One potential strategy may be the supplementation of the Branched Chain Amino 
Acid (BCAA) leucine, which has been established as a stimulator of protein synthesis 
through increased activity of the Mammalian Target of Rapamycin 
(mTOR) pathway.  Leucine supplementation has also been shown to attenuate protein 
degradation, increase mitochondrial function, and modulate insulin signaling. In a tumor 
implantation model of cancer cachexia, Leucine supplementation mitigated the loss of 
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lean mass and increased protein synthesis, without increasing tumor mass (Eley et al., 
2007). Thus, the therapeutic signaling produced from leucine supplementation may 
counter balance cachectic signaling induced by development of cancer. However, in 
pancreatic cancer cells leucine induced proliferation of tumor cells (K. A. Liu, Lashinger, 
Rasmussen, & Hursting, 2014). Additionally, Peters et al. demonstrated that leucine 
supplementation was unable to preserve body weight, but attenuated loss of muscle mass 
in glycolytic muscles (Peters et al., 2011). Although research has demonstrated the ability 
of leucine supplementation to attenuate muscle loss, little has been done to understand 
leucine’s effect on maintaining skeletal muscle metabolism during cancer cachexia. More 
research needs to be done to understand the mechanisms by which leucine is preserving 
muscle mass and how it interacts with the tumor and both muscle and systemic 
metabolism.  
Mitochondrial Function 
Mitochondria are crucial for metabolic reactions necessary for energy production 
by processing products of lipid and carbohydrate metabolism. This dual membraned 
organelle hosts highly oxidative processes to produce the energy necessary for the cell, 
insulating these reactive components from the cytosol. Disruption in mitochondrial 
function has been shown in various disease states ranging from diabetes to heart failure, 
suggesting an important role in the progression of these pathological conditions (Kelley, 
He, Menshikova, & Ritov, 2002; Ventura-Clapier, Garnier, & Veksler, 2008). Various 
studies have linked disruption in mitochondrial function to increased oxidative stress 
through generation of reactive oxygen species (ROS) and vice-versa (Venditti, Di 
Stefano, & Di Meo, 2013). In models of diet-induced obesity and type II diabetes, 
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mitochondrial dysfunction, oxidative stress, chronic inflammation, and physical inactivity 
are often associated with each other (Bach et al., 2005; Fischer et al., 2007; Kelley et al., 
2002). Mitochondrial dysfunction in muscle can lead to loss of muscle mass and function, 
impairing physical activity and overall health (Argilés, López-Soriano, & Busquets, 
2015; Romanello & Sandri, 2015). 
Mitochondrial function can be characterized through assessment of mitochondrial 
mass, metabolic efficiency, and maintenance. A main factor in mitochondrial mass is 
mitochondrial biogenesis, which can be defined as processes that increase mitochondrial 
mass and number.  In the world of exercise, increases in muscle mitochondria are thought 
to be largely responsible for increased resistance to fatigue and is one of the proven 
benefits of training. On the molecular level, mitochondrial biogenesis is highly 
influenced by current energy balance and associated signaling molecules. Factors such as 
a low ATP/ADP*AMP or NADH/NAD balance lead to increased AMP-activated protein 
kinase (AMPK) and Sirtuin 1 (SIRT1) activity respectively, modulating the activity of 
Peroxisome proliferator-activated receptor gamma co-activator (PGC-1α). PGC-1α is a 
key regulator of mitochondrial biogenesis through its interactions with key transcription 
factors, such as increased activation of nuclear respiratory factor 1 (NRF1) and 2 (NRF2) 
that leads to increased activity of mitochondrial transcription factor A (TFAM). TFAM 
drives the transcription and replication of mitochondrial DNA, consequently driving 
mitochondrial biogenesis (Jornayvaz & Shulman, 2010).  
In addition to exercise, other factors including inflammatory cytokines, caloric 
restriction, and various pharmacological agents have been shown to modulate 
mitochondrial biogenesis (Andreux, Houtkooper, & Auwerx, 2013; Jornayvaz & 
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Shulman, 2010). Furthermore, in some models of cancer cachexia, increased levels of 
interleukin-6 (IL-6) have been shown to decrease PGC-1α expression, resulting in 
disruption of mitochondrial biogenesis. To combat this disruption, both inhibition of IL-6 
signaling and exercise have been shown to attenuate these effects (White et al., 2012). 
Due to the relationship between mitochondrial disruption and muscle loss, preservation of 
mitochondrial function may be a vital mechanism to prevent further disruption of 
metabolic pathways already affected by cancer cachexia and prevent muscle wasting.  
Leucine Supplementation 
Branched chain amino acids (BCAAs) Leucine, Valine, and Isoleucine are 
essential amino acids that are primarily metabolized in the skeletal muscle. The liver, 
which would normally metabolize the majority of dietary amino acids, lacks branched 
chain amino transferase (BCAT) allowing for the BCAAs to be spared from hepatic 
metabolism and be utilized by tissues containing BCATs such as the skeletal muscles and 
the brain (Pedroso, Zampieri, & Donato, 2015). Dietary Supplementation of BCAAs, 
specifically leucine, have been shown to modulate protein synthesis and degradation in 
skeletal muscle. In fact, dietary leucine has been shown to increase protein synthesis 
through increased mTOR signaling, improve mitochondrial function, improve glucose 
metabolism, and enhance insulin signaling in various models and tissues (Li, Xu, Lee, 
He, & Xie, 2012; Pedroso et al., 2015). While the stimulation of mTOR and subsequent 
protein synthesis is widely known, Leucine’s effects on mitochondrial function, protein 




Attenuation of Protein Degradation.  Leucine supplementation has been shown 
to attenuate protein degradation in models of muscle wasting and protein deficiency 
(Baptista et al., 2010; Sugawara, Ito, Nishizawa, & Nagasawa, 2009). Baptista et al. 
demonstrated that leucine supplementation in a model of hind limb immobilization 
attenuates soleus muscle mass loss. This attenuation was accompanied with decreased 
expression of E3 ligases, potentially down regulating protein degradation via the 
Ubiquitin Proteasome System (UPS) pathway (Baptista et al., 2010). In rats fed a protein 
free diet, leucine supplementation attenuated protein degradation without increasing 
protein synthesis. The active form of protein light chain 3, a marker of autophagy, was 
significantly decreased while proteinase activity and ubiquitin ligase mRNA expression 
were not. These findings suggest that leucine may attenuate muscle protein degradation 
due to protein deficit through inhibition of autophagy, rather than increasing protein 
synthesis (Sugawara et al., 2009). Mirza et al compared the attenuation of protein 
degradation from leucine supplementation and from Ca-β-hydroxy-β-methylbutyrate 
(HMB) supplementation, a leucine metabolite, in C2C12 myotubes. They found that both 
leucine and HMB attenuated decreases in protein synthesis induced by proteolysis-
inducing factor (PIF), lipopolysaccharide, and angiotensin II, with HMB (50 μM) being 
more potent than Leucine (1 mM). Similar to the previously mentioned studies, this 
attenuation of protein degradation was measured as decreased activity of the UPS 
pathway through functional assessment of proteasome enzymatic activity and decreased 
western blot quantification proteasome subunits and ubiquitin ligases (Mirza, Pereira, 
Voss, & Tisdale, 2014). These findings show that leucine supplementation can attenuate 
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protein degradation independently of protein synthesis, further supporting its potential 
benefits for supplementation in highly catabolic states such as cachexia.  
Influence on Mitochondrial Function.  In addition to stimulation of protein 
synthesis and attenuation of protein degradation, leucine supplementation has been 
shown to modulate mitochondrial function, potentially through the activation of SIRT1 
and phosphorylation of AMPK. Leucine supplementation in C2C12 myotubes 
significantly increase mitochondrial content, expression of genes related to mitochondrial 
biogenesis, fatty acid oxidation, SIRT1 activity and gene expression, and AMPK 
phosphorylation compared to the controls (Liang, Curry, Brown, & Zemel, 2014). In a 
similar study, 24 h leucine incubation with C2C12 myotubes increased peroxisome 
proliferator-activated receptors β/δ (PPAR) expression and markers of mitochondrial 
biogenesis when compared to valine incubation (control).  Inhibition of PPARβ/δ resulted 
in decreased mitochondrial content and inhibition of mitochondrial oxygen consumption. 
In addition to mitochondrial effects, leucine incubation stimulated the phosphorylation of 
Akt and increased Glucose transporter type 4 (GLUT-4) content, subsequently increasing 
glucose uptake and resulted in increased PPARγ expression, fatty acid synthase 
expression, and lipid content suggesting improved lipid biogenesis and metabolism 
(Schnuck, Sunderland, Gannon, Kuennen, & Vaughan, 2016).  
In a mouse model of diet-induced obesity, leucine supplementation has been 
shown to increase mitochondrial biogenesis through increases in SIRT1 activity, resulting 
in decreases in PGC-1α acetylation, increasing mitochondrial mRNA (PGC-1α, NRF1, 
TFAM), and increased citrate synthase activity in both the liver and adipose tissue. 
Additionally, leucine supplementation also improved similar measures of oxidative 
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capacity in the skeletal muscle, decreased FOXO1 acetylation, and improved glucose 
metabolism (Li et al., 2012). These findings build a strong case for the improvement of 
mitochondrial function through Leucine supplementation, potentially improving 
outcomes of metabolic disorders like type 2 diabetes. Moreover, the ability of leucine to 
stimulate protein synthesis, attenuate degradation, improve mitochondrial function, and 
improve insulin sensitivity highlight its potential to improve outcomes of cancer 
cachexia.   
Combating Cachexia with anabolic stimulation or improvement of 
mitochondrial function.  In a few models of cancer cachexia, stimulation of the mTOR 
pathway has been shown to mitigate muscle loss (Chen et al., 2016; Eley et al., 2007).  
Chen et al supplemented Salidroside, a commonly consumed plant derivative, in LLC and 
CT-26 models of cancer cachexia and in C2C12 myotubes. They found that 
supplementation of Salidroside preserved muscle mass, improved food intake, and 
improved mTOR signaling without increasing tumor mass. Salidroside also improved 
outcomes in conjunction with a chemotherapeutic agent and improved mTOR signaling 
in C2C12 myotubes incubated with TNF-α (Chen et al., 2016). Utilizing a similar 
strategy, Eley et al. showed that supplementation of Leucine in a MAC16 implantation 
model of murine cancer cachexia improved protein synthesis, attenuated degradation, and 
preserved muscle mass, without increasing tumor mass. Western blot analysis of the 
skeletal muscle confirmed that these improvements were accompanied with improved 
mTOR signaling. Leucine supplementation in C2C12 also confirmed resistance to 
suppression of protein synthesis by PIF and angiotensin II (Eley et al., 2007). Together, 
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these studies support the use of nutritional anabolic stimulators in select cancer models to 
preserve muscle mass, potentially without increasing tumor burden.  
Other labs have considered increasing mitochondrial biogenesis or function to 
combat cachectic effects. In a LLC implantation model of murine cancer cachexia, PGC-
1α overexpression in the skeletal muscle increased mitochondrial biogenesis, content, and 
enzymatic activity. However, this increase in muscle mitochondrial function alone did 
not preserve muscle mass and may have increased tumor growth as tumor mass was 
significantly increased in the PGC-1α over expression group (Wang, Pickrell, Zimmers, 
& Moraes, 2012). In other models of muscle wasting, supplementation of resveratrol, an 
anti-oxidant and stimulator of mitochondrial function, has been shown to preserve 
mitochondrial function and attenuate muscle wasting (J. Liu et al., 2015). Resveratrol 
supplementation in a C26 adenocarcinoma model was reported to preserve lean, fat, and 
skeletal muscle mass potentially through attenuation of UPS degradation and Nuclear 
factor κ B (NFκB) inflammatory signaling (Shadfar et al., 2011). These studies support 
the use of nutritional supplements to improve protein synthesis, preserve mitochondrial 
function, and attenuate protein degradation to combat the catabolic effects of cachexia. 
Moreover, the supplementation of leucine has largely been beneficial in numerous 
disease models, with few or no associated side effects (Pedroso et al., 2015). However, 
one last connection remains to be confirmed: the influence of leucine on mitochondrial 
function under cancer cachexia. 
Therefore, this experiment aimed to determine the effects of dietary leucine 
supplementation on mitochondrial function within the LLC implantation model of cancer 
cachexia. A secondary aim was to analyze the effect of leucine on skeletal muscle mass 
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and function within cancer cachexia, allowing us to correlate these factors with 
mitochondrial function. Based on the current literature, we hypothesized that leucine 
should improve mitochondrial biogenesis within the LLC implantation model of cancer 
cachexia, with improved measures of protein synthesis and glucose metabolism. 
Furthermore, if those measures were improved, we expected preservation of skeletal 
muscle mass relative to the LLC group. 
The results from this experiment should further characterize the relationship 
between leucine supplementation, mitochondrial function, protein synthesis, maintenance 
of skeletal muscle, and LLC induced cachexia. Should the dietary supplementation of 
leucine prove beneficial under the influence of cancer, these effects may support 
therapeutic use to combat cachexia.  
Materials and methods 
Cell Culture 
The Lewis Lung Carcinoma (LLC) cell line utilized for this experiment was 
provided as a gift from the Carson Lab (University of South Carolina). The LLC cells 
were grown in Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine 
serum and penicillin/streptomycin, refreshing media every 48h. Just prior to tumor 
implantation, LLC cells were rinsed with phosphate buffered saline (PBS) and incubated 
with trypsin to release the cells from the dish. The cells were then suspended in PBS at a 
concentration of 1x107 cells per mL, such that each mouse received a 100 μl, 






All experimental and housing protocols were approved by the Institutional 
Animal Care and Use Committee of the University of Memphis.  
C57BL/6 male mice (n = 20), aged 7-8 weeks, were individually housed in a 
climate controlled room on a 12:12-h light-dark cycle. Upon arrival, all mice were 
allowed two weeks to acclimate to the new housing facilities before being divided into 4 
groups: Chow n = 5, Leucine Enriched (Leu) n = 5, Lewis Lung Carcinoma Implanted 
(LLC) n = 5 and LLC+Leu n = 5. The mice were allocated such that each group had 
equivalent average weight.  In the week preceding tumor implantation, the mice 
underwent pre-conditional testing including a run to fatigue, and fasting blood glucose 
measure. After two weeks, at approximately 9-10 weeks of age, LLC groups received the 
subcutaneous 100 μL injection of 1x106 LLC cells suspended in PBS while control 
groups received an equivalent volume of PBS alone. At this point, food was switched 
from standard chow to their respective experimental diets s, with Leu group diets being 
supplemented with Leucine 5% w/w.  For details on dietary composition of each diet, 
consult Table 1.  
Subsequently, the mice were monitored over the course of 28 days with an 
endpoint run to fatigue, blood draw, and glucose tolerance test conducted within a week 
of euthanasia. Food intake and body weight were measured every 48 h and the mice were 
checked daily for overall health. If the mice failed to eat over the course of 48 h, had 
severely impaired movement, lost >20% of body weight over 48 h, had a tumor larger 
than 2.5 cm in diameter, lacked responsiveness, or showed other severe signs of ill health, 
the mice were euthanized immediately. Mice were fasted 5 h prior to euthanasia, fasting 
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blood glucose measures, and blood draws. Mice were injected with puromycin (0.04 
µM/g BW) 30 minutes prior to tissue collection for assays measuring protein synthesis. 
Immediately before euthanasia, mice were anesthetized with isoflurane and tissues were 
harvested. For a list of collected tissues and respective weights, reference Table 2.  
For further biochemical analysis, the gastrocnemius of the hind limb was 
removed, weighed, snap frozen in liquid nitrogen, and stored at -80 °C.  A visual 
representation of how these methods were conducted throughout the experiment can be 
seen in Figure 1.  
Run to Fatigue 
During run to fatigue testing, mice were placed on the treadmill briefly to allow 
acclimation prior to testing. The acclimation, warmup, and run to fatigue was conducted 
on an incline of 5%. The pre and post run to fatigue starts with warmup period consisting 
of a 5 m/min walk, a 10 m/min walk, and 15 m/min run at 5 minutes each. After the 
warm up, the run to fatigue began and the timer was started. The mice ran at 20 m/min 
for 30 min before the speed was increased to 25 m/min for the remainder of the trial. If 
mice stopped running or slipped off the end of the treadmill, the mice were encouraged to 
return to running with a slight push with a gloved hand. Mice that continuously fell off or 
refused to run were removed and their time was taken. After two hours, the run to fatigue 
was ended. 
Fasting blood glucose 
Within the week preceding tumor implantation and within the last week of 
experimental conditions, mice were fasted 5 h before blood glucose levels were measured 




A portion of the excised gastrocnemius muscle was homogenized using a Kontes 
glass homogenizer in a 10:1 v/w ratio in ice cold Muller buffer containing protease and 
phosphatase inhibitors. The samples were centrifuged for 10 minutes at 10,000 g before 
the supernatant was removed into a separate microtube. The total protein concentration of 
this lysate was quantified using the Bradford protein assay. Samples were diluted to 3 μg 
protein/μL in appropriate amounts of diluent buffer and 5X Lane Marking Reducing 
Sample Buffer and were heated at 95° C for 10 minutes.  Samples were then resolved via 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on a 4-15% 
gradient gel and subsequently transferred on to a PVDF membrane. The blot was then 
blocked with 5% BSA for 1 h before being incubated in primary antibody according to 
manufacture specification. After multiple washes (3 washes at 5 min each) in Tris-
buffered saline-0.1% Tween 20 (TBST) blots were incubated in appropriate HRP-
conjugated secondary antibodies (1:5,000 in 5% BSA for 2 h). For more details on 
western blot conditions and source of antibodies, reference Table 2.  The blots were then 
washed again in TBST before being visualized with a chemiluminescent agent and 
imaged using a Fotodyne® 60-7020 bench top imager. All bands were quantified via 
densitometry via ImageJ.  
Protein synthesis was quantified with a western blot adaptation of the SUrface 
SEnsing of Translation (SUnSET) technique (Schmidt, Clavarino, Ceppi, & Pierre, 
2009). The puromycin injected (0.04µMol/ g BW) 30 minutes prior to sacrifice is 
incorporated into elongating peptide chains, preventing further peptides from binding. 
Consequently, the peptides with incorporated puromycin are released from the ribosome, 
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accumulating in the cell. At low levels, quantification of these puromycin incorporated 
peptide chains directly correlates with protein synthesis. Utilizing the western blot 
methodology, immunoblotting with a puromycin antibody allow quantification of protein 
synthesis. 
After imaging, blots were stained with Ponceau to visualize bound protein and 
were imaged using the bright field setting on the Fotodyne® imager. Immunoblotted 
proteins were then normalized to the inverted densitometry quantification of the Ponceau 
stain. Data is presented as relative integrated optical density (IOD) normalized to inverted 
densitometric quantification of ponceau staining with the control group average set to 1.   
Statistical Analysis 
All statistical analyses were conducted using GraphPad Prism 7® software. All 
data are presented as means + Standard Error of Mean (SEM). Statistical significance was 
set at α = 0.05. Western blot data were analyzed via two-way analysis of variance 
(ANOVA). Pre-planned t-tests were used to examine the effect of LLC, the effect of 
leucine in the control condition, and the effect of leucine in the LLC condition. 
Results 
All mice in the Chow, Leu, and LLC groups completed the study with no 
complications. Within the LLC+Leu group, one mouse experienced tumor growth that 
impaired mobility, requiring euthanasia three days before the rest. Another mouse within 
the LLC+Leu group did not develop a tumor and resulting data was excluded from 
analysis (n = 4).  
Experimental effects on food intake and body composition.  Neither LLC 
implantation nor leucine supplementation had significant effects on body weight (Figure 
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2A) or daily food intake (Figure 2B) over the course of this experiment.  Leucine had no 
effect on tumor growth (Table 3). There were no independent effects of LLC 
implantation or leucine supplementation on tumor free body mass, epidydimal fat mass, 
gastrocnemius mass, or hind limb mass, calculated as the sum of the hind limb muscles 
taken, between groups (Figure 2C-E). Within the LLC implantation groups preplanned t-
tests revealed a significant decrease in gastrocnemius and hind limb mass of the leucine 
supplemented group when compared to the control chow group.   
Experimental effects on skeletal muscle function and fasting glucose.  A run 
to fatigue test was conducted the week preceding euthanasia and tissue collection. There 
was a main effect of LLC implantation (p>0.05) to decrease endurance running 
performance measured by the run to fatigue (Figure 3A). Within the same week, fasting 
blood glucose was measured and recorded via glucometer. An interaction between LLC 
implantation and leucine supplementation was present within the final fasting glucose 
measures, with a T-test revealing a significant decrease in the LLC+Leu group compared 
to the LLC group (Figure 3B). Considering individual changes in response to 
experimental conditions, a change in fasting glucose was calculated for each mouse, as a 
percent difference of pre-experimental measures to post-experimental measures of fasting 
glucose (Figure 3C). Considering % change from pre-experimental measures, a T-test 
revealed that leucine supplementation in the LLC implanted mice induced a significant 
decrease in fasting glucose (P<0.05) compared to the control chow group.   
Experimental effects on markers of mitochondrial function within skeletal 
muscle.  Western blot analysis in the gastrocnemius muscle revealed effects of LLC 
implantation and leucine supplementation on protein expression levels of various 
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mitochondrial markers. An interaction between LLC implantation and leucine 
supplementation was present within PGC-1α expression levels (Figure 4A), a marker of 
mitochondrial biogenesis. A significant increase of PGC-1α protein levels in the 
LLC+Leu group was seen relative to LLC. Cytochrome C (Figure 4B), a marker of 
mitochondrial content, showed a main effect LLC implantation decreasing expression 
levels, with a significant decrease (p<0.05) in the LLC group compared to the Chow. 
Analysis of CV-ATPA5 (Figure 4C), commonly known as ATP synthase or 
mitochondrial complex V, showed a main effect of LLC implantation reducing 
expression levels. Levels of CIII-UQCRC2 (Figure 4D), a component of complex 
mitochondrial complex III or ubiquinol-cytochrome c reductase complex, showed a main 
effect of LLC implantation, resulting in significant decreases (p<0.05) in both LLC and 
LLC+Leu groups, when compared to the control. For both CII-SDHB (Figure 4E), a 
subunit of succinate dehydrogenase or complex II, and CI-NDUFB8 (Figure 4F), subunit 
of mitochondrial complex I or NADH dehydrogenase, expression levels were not 
significantly different between groups.  
Experimental effects on protein synthesis.  Protein synthesis was quantified by 
western blot adaptation of the SUnSET technique, measuring incorporation of injected 
puromycin into elongating peptides. Within the gastrocnemius, there was a main effect of 
LLC implantation for decreased puromycin levels (Figure 5A), Additionally, a significant 
decrease (p<0.05) was detected in the LLC+Leu group when compared to the control. 
Interestingly, there was no effect of Leucine or LLC tumor implantation on the 
phosphorylation of mTOR (Figure 5B).  
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Experimental effects on phosphorylation of STAT3.  The proportion of STAT3 
phosphorylation can indicate state of inflammation. There was a main effect of LLC 
implantation (P<0.05) to increase STAT3 phosphorylation (Figure 5C). In the non-tumor 
groups, leucine significantly decreased STAT3 phosphorylation (p<0.05), but this was 
not maintained in the tumor implantation groups.  
Discussion 
Preservation of lean mass is often the goal when treating cachexia, as loss of lean 
mass is associated with increased mortality within cancer and many other pathological 
populations including: heart failure, liver cirrhosis, sarcopenia, and more (Kalafateli, 
Konstantakis, Thomopoulos, & Triantos, 2015; Nanri et al., 2010; Pocock et al., 2008; 
Visser & Schaap, 2011). Cachectic signaling secreted by the tumor induces a chronic 
state of inflammation, which has been linked with muscle wasting and disruption of 
energy metabolism. Consequently, strategies utilizing nutritional intervention and 
exercise can support maintenance of skeletal muscle and improve  metabolic measures, 
with reduced interactions with pharmacological therapies for cancer treatment (Argilés, 
Busquets, López‐Soriano, Costelli, & Penna, 2012; Baldwin et al., 2012). In addition to 
improving caloric and micronutrient content, there is evidence that utilization of 
nutraceuticals, food based nutrients at pharmacological doses, can provide benefits 
through improvements in metabolic signaling in skeletal muscle.  
This research explores whether the Branched Chain Amino Acid (BCAA) leucine 
can improve metabolic measures impaired by cachexia. Within the models of exercise, 
diet, and disease, leucine has been shown to improve protein synthesis and preserve 
muscle mass. In non-pathological models, leucine supplementation increases 
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mitochondrial biogenesis and content. The focus of this experiment was mitochondrial 
biogenesis, as loss of mitochondria can be associated with cachexia and muscle wasting. 
Therefore, our experiment aimed to elucidate how leucine signaling influences 
mitochondrial biogenesis within the LLC model of cancer cachexia and whether that 
interaction affects muscle mass and function.  
Both leucine supplementation and LLC implantation had limited effects on 
food intake and body composition.  Neither 5% leucine supplementation nor LLC 
implantation affected food intake over the course of the experiment, suggesting the 
absence of anorexia. Even minor anorexic tendencies can result in large differences in 
body weight. Since food intake did not differ between groups, we can infer that the 
influences of LLC implantation on body composition are independent of anorexia. 
However, neither LLC implantation nor leucine supplementation independently affected 
tumor free body weight, fat mass, or muscle mass (Figure 2C-D). This is in contrast to 
previous studies which have shown LLC-induced decreases in tumor free body mass and 
gastrocnemius weight when compared to controls (Puppa, Gao, Narsale, & Carson, 
2014). Interestingly, in the current study leucine supplementation in the LLC condition 
resulted in a decrease of muscle mass in the gastrocnemius. This contrasts with other 
reports that supplementing leucine within models of cachexia preserved muscle mass 
(Eley et al., 2007; Peters et al., 2011).  
Similar to our study, Peters et al. utilized a tumor implantation model of cachexia 
to reveal dose dependent effects of dietary leucine on preservation of muscle mass. The 
C-26 adenocarcinoma model induced significant decreases in body and muscle mass over 
the course of 21 days, a more acute window of cachexia (Peters et al., 2011). The authors 
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noted that this model progressively develops anorexia, as noted by a significant decrease 
in food intake on the final day. Providing 14.6% leucine preserved the gastrocnemius and 
tibialis anterior under tumor burden, but lower leucine content of 9.6% did not result in a 
significant preservation of body or muscle mass, similar to our study. While both diets 
initially appear to have higher leucine content than our 5% supplementation (w/w), the 
9.6%, and 14.6%, also accounts for leucine from dietary protein. The shortened 
experimental period, leucine dosage, and progression into anorexia may influence rates of 
muscle loss within their model, which may contribute to different results for the present 
study.  
In a study analyzing the effect of branched chain amino acids in a MAC16 model 
of cancer cachexia, Eley et al. demonstrated that leucine supplementation preserves 
soleus muscle mass and increases protein synthesis in the gastrocnemius when compared 
to the control tumor group (Eley et al., 2007). While these results are, again, in contrast to 
ours, methodology differed as leucine supplementation was administered daily in a PBS 
solution (1g Leucine/kg of bodyweight) by gavage, only after tumor groups had lost 5% 
of their starting body weight. Additionally, the mice were sacrificed after 20% of their 
starting body weight had been lost, a period of 5 days, ensuring that the main outcome of 
cachexia, significant loss of body mass, was present (van Hall et al., 2008). Despite 
measuring similar outcomes in a similar disease state, Eley’s acute delivery of leucine 
supplementation into mice progressing into cachexia is in stark contrast to the study 
where the diet provided 5% w/w of leucine, immediately after LLC implantation. 
The fact that our mice did not experience the predicted decrease in body or 
muscle mass under LLC implantation, as seen in previous studies or other models, 
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suggest that they did not develop a severe state of cachexia. Moreover, the decrease in 
muscle mass found with leucine supplementation in conjunction with LLC implantation 
was not expected, suggesting a different state of disease progression than other studies. 
Despite, not experiencing pathological wasting, our analysis of protein synthesis and 
mitochondrial function suggest that some cachectic signaling may be occurring, perhaps 
in a state of pre-cachexia.  
Leucine supplementation and LLC implantation had limited effects muscle 
protein synthesis. In the current study, LLC implantation significantly impaired protein 
synthesis, as demonstrated by decreases in puromycin labeling in both LLC and 
LLC+Leu groups (Figure 4A). Unexpectedly, the administration of leucine supplemented 
chow was unable to induce protein synthesis in the skeletal muscle in both the control 
group and the LLC inoculated mice.  Similarly, skeletal muscle mTOR activity was not 
increased with Leucine supplementation (Figure 5B). Interestingly, leucine 
supplementation in the LLC model resulted in a decrease puromycin incorporation, and 
unaltered mTOR phosphorylation. This discrepancy between puromycin, a functional 
measure of protein synthesis, and mTOR phosphorylation, an indicator of anabolic 
signaling, suggests an effect of cachectic signaling within the LLC implantation groups 
that is occurring downstream of mTOR activation.  
The disconnect between measurements of protein synthesis and mTOR activation 
may result from influences of inflammation. A main effect of LLC implantation is 
increased phosphorylation of STAT3, a marker of inflammation, as seen in the skeletal 
muscle. This contrasts with the decreased proportions of STAT3 phosphorylation in 
Leucine supplemented group without LLC implantation (Figure 5C). These findings 
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show that inflammatory signaling is increased by LLC implantation and decreased by 
leucine supplementation, but leucine supplementation is not sufficient to decrease muscle 
inflammatory signaling in the pre-cachectic condition. 
While the inflammatory signaling induced by LLC implantation indicates the 
presence of cachectic signaling, chronic inflammation may also explain the reduced 
efficacy of leucine supplementation within our study. In a state of induced sepsis, 
stimulation of mTOR by leucine supplementation was blocked. To demonstrate that not 
all anabolic signaling was blocked, exogenous insulin like growth factor-1 (IGF1) 
activated the same pathways that were not responsive to leucine with sepsis (Lang & 
Frost, 2004). These findings suggest that under inflammatory conditions, skeletal muscle 
may not respond to anabolic signaling by leucine supplementation.  In a model of age 
induced muscle loss, antioxidants restored anti-catabolic blunting by leucine 
supplementation (Marzani et al., 2008). These findings suggest that anabolic signaling is 
heavily influenced by the state of inflammation. 
While inflammation can be attributed to infection and tumor secretion, the 
generation of reactive oxygen species (ROS) can also contribute. Interestingly, 
mitochondrial dysfunction can lead to increased ROS generation if the highly oxidative 
reactions utilized to produce energy are exposed to the cytosol. There is ample evidence 
that mitochondrial dysfunction can lead to inflammation. Within the model of TNFR1-
associated periodic syndrome (TRAPS), a disorder characterized by fever and severe 
localized inflammation, there are higher levels of mitochondrial ROS (mtROS). The 
increased mtROS was correlated with increased activation of Jun N-terminal kinase 
(JNK) and p38, as characterized by persistent Mitogen-Activated Protein Kinase 
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(MAPK) activation. Inhibition of mtROS inhibited MAPK activation and the production 
of inflammatory cytokines (Bulua et al., 2011).  
These findings coincide with Barreiro et al. who revealed increases in protein 
carbonylation, a marker of protein oxidation, and 3-nitrotyrosine, a marker of reactive 
nitrogen species production, in the gastrocnemius of cachectic mice. In addition to 
evidence of increased ROS and reactive nitrogen species (RNS) induced oxidation, 
antioxidant enzymes were not significantly increased, suggesting potential inefficiencies 
in mitigating oxidative damage (Barreiro et al., 2005).  
However, there is also evidence that inflammation can induce mitochondrial 
dysfunction. Within the ApcMin/+ model of cancer cachexia, the severity of the cachectic 
condition is related with decreases in mitochondrial biogenesis and content, as well as 
disruption in mitochondrial maintenance. Administration of an IL-6 receptor antibody 
improved mitochondrial function while IL-6 over expression accelerated muscle wasting 
and suppressed PGC-1α expression (White et al., 2012). These findings reinforce the 
relationship between mitochondrial dysfunction and inflammation, providing evidence 
that aggravation of each can induce aggravation of the other.   
In addition to inflammation, mTOR has been established as a modulator of 
mitochondria biogenesis. Cunningham et al. revealed that inhibition of mTOR by 
rapamycin in skeletal muscle cells decreases transcription of PGC-1α and NRFs, thereby 
decreasing mitochondrial gene expression and oxidative capacity. Using computational 
genomics, the transcription factor Yin-Yang 1 (YY1) was identified as a common target 
of mTOR and PGC-1α. The rapamycin dependent inhibition relies on YY1, resulting in 
failure to interact and coactivate with PGC-1α. Additionally, YY1 knockdown decreased 
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mitochondrial gene expression and respiration (Cunningham et al., 2007). This 
relationship between mTOR and PGC-1α effectively link protein synthesis to 
mitochondrial biogenesis, as inhibition of one may also inhibit the other.  
Leucine supplementation improves mitochondrial biogenesis under LLC 
implantation.  Despite the unexpected lack of effect on protein synthesis, leucine did 
improve mitochondrial biogenesis as PGC-1α was increased in the LLC+Leu group 
relative to the LLC group (Figure 4A). This is in agreement with in vitro studies 
demonstrating that leucine supplementation in the media significantly increased PGC-1α 
expression in C2C12 myotubes (Liang et al., 2014). Considering mitochondrial content, 
there were no significant differences between the LLC and LLC+Leu groups, suggesting 
no functional increase in mitochondrial biogenesis by leucine in to the LLC implantation 
model. This was corroborated by the decreases in Cytochrome C and CIII in the LLC 
implanted mice relative to the control (Figure 4B and 4D). The increase in PGC-1α 
suggests signaling for mitochondrial biogenesis; however, without a functional protein 
synthesis pathway mitochondrial biogenesis cannot occur as the majority of 
mitochondrial proteins are synthesized in the cytosol and transported into the 
mitochondria.  
Simply increasing mitochondrial biogenesis or content may not be enough to 
impart protection from tumor-induced muscle wasting. Wang et al. utilized a transgenic 
Muscle Creatine Kinase (MCK)-PGC-1α mouse strain overexpressing PGC-1α skeletal 
muscle to explore influences of mitochondrial content in muscle preservation under 
cachexia. Like this current study, they utilized an LLC implantation model into their 
MCK-PGC-1α strain with C57BL/6 wild-type as the control. The MCK-PGC-1α strain 
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maintained upregulation of PGC-1α under tumor burden, resulting in increased 
mitochondrial biogenesis and content within the skeletal muscle. This coincided with 
increased PGC-1α, associated mRNA signaling, and mitochondrial content. Despite 
increased mitochondrial function, the MCK-PGC-1α groups experienced significantly 
decreased tumor free body weight, no preservation of skeletal muscle, and an unexpected 
increase in tumor mass. These changes may be attributed to increased secretion of 
skeletal muscle myokines as the MCK-PGC-1α groups experienced elevated IL-6 relative 
to their respective wild-type control (Wang et al., 2012).  These results resonate with 
ours, as leucine increased PGC-1α without preserving muscle mass or increasing protein 
synthesis under tumor burden. However, leucine supplementation did not increase 
mitochondrial content or increase inflammation as seen in the MCK-PGC-1α mice 
suggesting a more complex signal by leucine.  
While increases in skeletal muscle PGC-1α alone may not be sufficient to protect 
from tumor-induced muscle atrophy, increasing mitochondrial content through 
pharmacologic or nutraceutical means may impart some benefit. The use of resveratrol, 
an established anti-oxidant and stimulator of mitochondrial function, has been used to 
preserve body mass in cachectic and glucocorticoid induced models of muscle wasting(J. 
Liu et al., 2015; Shadfar et al., 2011). In a model of dexamethasone induced muscle 
atrophy, resveratrol reversed loss of mitochondrial content and preserved muscle mass, 
highlighting mitochondrial dysfunction as a key factor in muscle loss (J. Liu et al., 2015). 
While Shadfar et al did not analyze mitochondrial function, they demonstrated that 
resveratrol can inhibit skeletal and cardiac muscle atrophy under a C26 adenocarcinoma 
implantation model of cachexia, highlighting how the antioxidant capabilities inhibits 
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NFκB (Shadfar et al., 2011).  These papers in conjunction suggest that nutraceutical 
inhibition of inflammatory signaling and restoration of mitochondrial function can 
preserve muscle mass without targeting mTOR.  
BCAAs, glucose, and insulin. In addition to impairing mitochondrial function 
and inducing systemic inflammation, insulin resistance is a common symptom among 
patients with cachexia. There is even some evidence that insulin resistance precedes the 
onset of cachectic symptoms, and continues to worsen as cachexia progresses (Honors & 
Kinzig, 2012). Interestingly, leucine has been shown to have a complex interaction with 
insulin signaling and glucose metabolism.  In cases of obesity and type II diabetes, 
endogenous elevation of circulating BCAAs has commonly been associated with the 
development of insulin resistance (Lynch & Adams, 2014; McCormack et al., 2013). This 
contrasts with various studies reporting increases in insulin sensitivity and increased 
glucose tolerance with leucine supplementation.  
Within this study, leucine supplementation decreased fasting glucose under tumor 
burden, resulting in a significant decrease from pre-experimental measures when 
compared to the chow group. These findings align with reports of leucine increasing 
insulin sensitivity as signaling from exogenous supplementation may be inherently 
different than endogenous increases.  
This discrepancy may involve reasons why circulating BCAAs could increase 
without exogenous supplementation. A common instance of increased circulating BCAAs 
is during the process of muscle breakdown. As proteins within the muscle are broken 
down, the amino acid components are released into circulation to be recycled. As 
mentioned previously, the liver has a decreased ability to metabolize BCAAs due to the 
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lack of BCAT, resulting in an increase of BCAAs in circulation. Alternatively, BCAAs 
have been shown to be elevated in obese individuals and may predict the onset of type II 
diabetes (McCormack et al., 2013). BCAAs may be elevated by the body to enhance 
insulin signaling and glucose metabolism, only to experience desensitization of 
therapeutic signaling effects.  
Within the realm of cachexia, increased circulating levels of BCAAs have been 
correlated with increased rates of protein turnover (Argiles, Costelli, Carbo, & 
LopezSoriano, 1996). While the cause is not certain, it is thought that the muscle wasting 
and overall catabolic condition induce the release of amino acids into circulation for 
increased energy demands of both the muscle and tumor. A slim possibility is that the 
cachectic processes/signals that induce insulin resistance and inflammatory signaling, 
also induce release of BCAAs. Considering these factors, future research should explore 
differences between chronic and acute leucine supplementation. 
In some agreement with our hypothesis, our experiment demonstrates that leucine 
supplementation increased signaling of mitochondrial biogenesis under cachexia. 
However, despite increased PGC-1α within the LLC+LEU group, this did not result in 
significant improvements in mitochondrial content, as defined by cytochrome C and 
mitochondrial complexes. Unexpectedly, leucine supplementation did not preserve 
muscle mass or increase protein synthesis, contrary to other studies utilizing leucine 
within cachexia (Eley et al., 2007; Peters et al., 2011). While our results show 
improvement in fasting blood glucose and attenuation of inflammatory signaling, it is 
uncertain whether the 5% leucine supplementation provided overall benefit, as LLC 
implantation and leucine supplementation in conjunction, resulted in significantly 
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decreased gastrocnemius and hind limb muscle mass. Based on the current results of this 
study, it would be difficult to recommend leucine supplementation in the manner it was 
applied within our experiment. Major aspects of leucine signaling are still unknown, as it 
has not been revealed how a single amino acid induces such an array of signaling. As 
with many signaling agents, desensitization or downregulation of associated signaling 
may occur, suggesting more acute durations of supplementation may be more beneficial. 
These findings answered our main question, but left us with more. Stimulation of 
anabolic signaling may provide support to many models of disease.  However, more 
research is needed to elucidate how leucine signaling is induced and how aspects of 
cachexia block leucine induced mitochondrial biogenesis.  
Limitations and Future Direction 
This study is limited by two main factors: low sample size and lack of cachectic 
characteristics. The current data represents only half of the planned mice, as the 2nd 
cohort of mice is currently undergoing experimental conditions. Additionally, the absence 
of tumor generation for one mouse compromised statistical analysis of LLC+Leu group, 
reducing sample size (n = 4). In the remaining mice, decreased cachectic characteristics 
can be attributed to shortened period under tumor burden. Within the LLC+Leu group, 
one mouse (001) required premature euthanasia due to health complications. Another 
mouse experienced ulceration of the tumor, prompting euthanasia the next day. Despite 
the enlarged tumor mass, limited effects of cachexia were seen within these mice. 
However, with the completion of the next cohort, differences between conditions may 
become more pronounced, allowing us improved comparison of experimental conditions.  
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Considering future experimentation, metabolic aspects should be measured within 
glycolytic muscle or the liver, as cachexia and leucine may affect these tissues 
differently. Additional markers of mitochondrial function and protein synthesis can be 
assessed via western blot analysis to define where disruptions occur along the signaling 
pathways. While phosphorylation of STAT3 indicates state of inflammatory signaling, 
direct measures of inflammatory cytokines in the blood can confirm the presence of 
cachectic signaling. If the cachectic signaling is confirmed in circulation, we could 
potentially elucidate interaction between Leucine supplementation and inflammatory 
signaling. Of particular interest are upstream promoters of PGC-1α (AMPK and SIRT1), 
markers of mitochondrial maintenance (mitochondrial fusion and fission proteins), and 
aspects of protein degradation pathways.  Future studies should examine the effect of 
leucine supplementation in combination with anti-oxidants to further enhance 




Table 1: Composition of Diets 
The composition of each diet is listed, with diets being identical save for the addition of 
5% Leucine w/w and red dye.   




Table 2: Antibody information 
The antibodies used throughout this experiment, source of antibody, dilution, and 























OXPHOS Cocktail abcam 1:2000 Overnight Mouse Cell Signaling 1:5000 2 h
Puromycin Millipore 1:5000 Overnight Mouse Cell Signaling 1:5000 2 h
PGC-1α Abcam 1:2000 Overnight Rabbit Cell Signaling 1:5000 2 h
P-STAT3 Cell Signaling 1:2000 Overnight Rabbit Cell Signaling 1:5000 2 h
STAT3 Cell Signaling 1:5000 Overnight Rabbit Cell Signaling 1:5000 2 h
P-MTOR Cell Signaling 1:2000 Overnight Rabbit Cell Signaling 1:5000 2 h
MTOR Cell Signaling 1:5000 Overnight Rabbit Cell Signaling 1:5000 2 h
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Table 3: Body composition 
Upon euthanasia, mice were weighed and tissues were collected. Body, muscle, tumor, 












BW Pre (g) 22.1 ± 1.6 22.7 ± 1.8 22.0 ± 1.0 21.9 ± 0.9
BW Sac (-Tumor) (g) 23.0 ± 1.3 23.9 ± 2.0 22.9 ± 1.4 21.5 ± 1.6
Tumor (g) 1.7 ± 1.1 1.5 ± 1.0
Sol (mg) 9.5 ± 0.6 8.8 ± 1.4 9.3 ± 0.9 7.8 ± 2.2
Plant (mg) 17.1 ± 0.6 16.9 ± 1.5 17.8 ± 1.4 14.6 ± 2.3
Gastrocnemius (mg) 119.3 ± 11.3 119.2 ± 11.2 121.2 ± 7.0 105.2 ± 11.1
TA (mg) 42.1 ± 3.9 42.9 ± 5.2 39.4 ± 6.3 36.0 ± 6.5
EDL (mg) 10.8 ± 1.9 10.3 ± 1.2 10.7 ± 1.4 8.5 ± 1.9
Quad (mg) 87.9 ± 9.2 90.1 ± 8.9 90.3 ± 3.1 73.5 ± 9.0
Total Hindlimb (mg) 198.7 ± 17.3 198.1 ± 20.0 198.4 ± 13.7 172.0 ± 23.3
Liver (mg) 1055.2 ± 78.5 1019.1 ± 236.1 1198.1 ± 86.5 1142.4 ± 143.4
Spleen (mg) 63.5 ± 4.0 74.6 ± 25.8 140.4 ± 52.3 151.9 ± 69.5
Epi Fat (mg) 363.4 ± 48.9 424.7 ± 128.8 352.1 ± 60.2 290.3 ± 113.4
Heart (mg) 150.8 ± 12.9 165.7 ± 45.9 121.9 ± 5.0 135.7 ± 37.8
Control LLC
Chow Leu LLC LLC + Leu






Figure 1 – Experimental Design:  
Male, wild type C57BL/6 mice (n = 20), aged 7-8 weeks old were individually housed 
and allowed ad libitum food intake of standard chow to acclimate to the facility for two 
weeks. In the week, preceding tumor implantation, mice underwent pre-experimental 
testing including a fasting glucose, blood draw, and run to fatigue exercise test. At the 
end of their acclimation period, the mice were divided into 4 equal groups: Chow, 
Leucine (Leu), Chow + Lewis Lung Carcinoma (LLC), and Leu + LLC (n = 5). LLC 
groups received an injection of 1x106 cells suspended in PBS subcutaneously while Non-
LLC groups received a PBS injection of equivalent volume. Leu groups received a diet 
consisting of 5% Leu (w/w). The mice were monitored for 4 weeks post-injection and 
post experimental testing was completed in the final week preceding euthanasia and 
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Figure 2 –  Body mass and composition:  
A) Body weights (g) and B) daily food intake (g/day) of the mice were recorded over 
time, with the “0” time point representing tumor injection. At the end of the experimental 
period, C) tumor free body weight, D) tumor mass, E) epidydimal fat mass normalized to 
tumor free body weight, and F) average gastric weight normalized to tibia length were 
calculated. Data are represented as mean + SEM. Significance was set at p>0.05. τ 
significant base on t-test.  
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Figure 3 – Endurance performance and fasting glucose:  
A) The post-experimental run to fatigue is presented in minutes with a maximum time of 
120. B) Post experimental fasting blood glucose levels measured via glucometer were 
recorded after a 5h fasting period, C) Change in fasting blood glucose was calculated as a 
percent change from pre-implantation measures within the last week of tumor 
implantation. Data are represented as mean + SEM. Significance was set at p>0.05. τ 
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Figure 4 – Measures of mitochondrial biogenesis in the gastrocnemius:  
Utilizing western blot analysis of the gastrocnemius tissue, expression of proteins key to 
mitochondrial biogenesis and content were quantified. Values for A) PGC-1α, B) 
Cytochrome C, C) CV-ATP5A, D) CIII-UQCRC2, E) CII-SDHB, and F) CI-NDUFB8 
are presented as IOD normalized to Ponceau staining. * indicates significant difference 
calculated by repeated measures from a Two-Way ANOVA; τ indicates significant 
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Figure 5- Measures of Protein synthesis and other metabolic signaling:  
Utilizing the Western Blot adaptation of the SUnSET technique, protein synthesis was 
quantified within the gastrocnemius through the measurement of A) puromycin, 
presented as IOD normalized to inverted densitometry of Ponceau staining. The 
phosphorylated forms of B) MTOR (P-MTOR) and C) STAT3 (P-STAT) are presented 
as a ratio over its non-phosphorylated form. Data are represented as mean + SEM. 
Significance was set at p>0.05. * indicates significant difference calculated by repeated 
measures from a Two-Way ANOVA; τ indicates significant difference calculated by t-
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